Based on our observation that BMAL1-HIF2α heterodimers are more sensitive to suppression by the HIF2α antagonist PT2399 than ARNT-HIF2α heterodimers are, we predicted that suppression of tumor growth by PT2399 would be greater at the time of day when BMAL1 is more active. This evidence concerns the gene EPAS1 and neoplasm.